Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Assisted Reproduction and Genetics
Published in: Journal of Assisted Reproduction and Genetics 8/2015

01-08-2015 | Fertility Preservation

IVF for fertility preservation in breast cancer patients—efficacy and safety issues

Authors: M. Shapira, H. Raanani, D. Meirow

Published in: Journal of Assisted Reproduction and Genetics | Issue 8/2015

Login to get access

Abstract

Background

Potential risks on future fertility have become a dominant issue in consultation and management of newly diagnosed young cancer patients. Several fertility preservation strategies are currently available. Of those, ovarian stimulation followed by IVF and embryo cryopreservation is the most established one and is especially applicable in reproductive aged breast cancer patients.

Aim

The aim of this study is to provide a comprehensive review on ovarian stimulation and IVF for fertility preservation in newly diagnosed breast cancer patients.

Methods

Review of relevant literature is available through PubMed and Google scholar.

Results

The use of IVF for fertility preservation in breast cancer patients raises dilemmas regarding efficacy and safety of controlled ovarian stimulation. Among these are the suggested role of malignancy and BRCA mutation in reducing ovarian response to stimulation, strategies designated to protect against hyper-estrogenic state associated with stimulation (co-treatment with tamoxifen or letrozole), and possible adjustments to accommodate oncologic-related time constraints.

Conclusion

Ovarian stimulation followed by IVF forms an important fertility preservation strategy for newly diagnosed young breast cancer patients, though live born rates following thawed embryo transfer in these patients are still lacking. Recent advances in controlled ovarian stimulation protocols provide practical options for some of the challenges that breast cancer patients present.
Literature
1.
Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA. 2013;309(8):800–5.PubMedCrossRef
2.
Merlo DF et al. Breast cancer incidence trends in European women aged 20–39 years at diagnosis. Breast Cancer Res Treat. 2012;134(1):363–70.PubMedCrossRef
3.
Azim Jr HA et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2013;31(1):73–9.PubMedCentralPubMedCrossRef
4.
Anders CK et al. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol. 2011;29(1):e18–20.PubMedCentralPubMedCrossRef
5.
Anders CK et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324–30.PubMedCrossRef
6.
Cardoso F et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer. 2012;48(18):3355–77.PubMedCrossRef
7.
Meirow D et al. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol. 2010;53(4):727–39.PubMedCrossRef
8.
Demeestere I et al. Multiple approaches for individualized fertility protective therapy in cancer patients. Obstet Gynecol Int. 2012;2012:961232.PubMedCentralPubMed
9.
Lee SJ et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917–31.PubMedCrossRef
10.
Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001;7(6):535–43.PubMedCrossRef
11.
Okanami Y et al. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast Cancer. 2011;18(3):182–8.PubMedCrossRef
12.
Letourneau JM et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710–7.PubMedCentralPubMedCrossRef
13.
Schover LR et al. Having children after cancer. A pilot survey of survivors’ attitudes and experiences. Cancer. 1999;86(4):697–709.PubMedCrossRef
14.
Loren AW et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10.PubMedCrossRef
15.
Partridge AH et al. First international consensus guidelines for breast cancer in young women (BCY1). Breast. 2014;23(3):209–20.PubMedCrossRef
16.
Peccatori FA et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi160–70.PubMedCrossRef
17.
Moore HC et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923–32.PubMedCrossRef
18.
Courbiere B et al. Emergency IVF for embryo freezing to preserve female fertility: a French multicentre cohort study. Hum Reprod. 2013;28(9):2381–8.PubMedCrossRef
19.
20.
Michaan N et al. Ovarian stimulation and emergency in vitro fertilization for fertility preservation in cancer patients. Eur J Obstet Gynecol Reprod Biol. 2010;149(2):175–7.PubMedCrossRef
21.
Robertson AD, Missmer SA, Ginsburg ES. Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy. Fertil Steril. 2011;95(2):588–91.PubMedCrossRef
22.
Cardozo ER et al. Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience. J Assist Reprod Genet. 2015;32(4):587–96.PubMedCrossRef
23.
Ovarian tissue cryopreservation: a committee opinion. Fertil Steril. 2014;101(5):1237–43.
24.
Cobo A et al. Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients? Fertil Steril. 2013;99(6):1485–95.PubMedCrossRef
25.
Cobo A et al. Obstetric and perinatal outcome of babies born from vitrified oocytes. Fertil Steril. 2014;102(4):1006–15.e4.PubMedCrossRef
26.
Potdar N, Gelbaya TA, Nardo LG. Oocyte vitrification in the 21st century and post-warming fertility outcomes: a systematic review and meta-analysis. Reprod Biomed Online. 2014;29(2):159–76.PubMedCrossRef
27.
Garcia-Velasco JA et al. Five years’ experience using oocyte vitrification to preserve fertility for medical and nonmedical indications. Fertil Steril. 2013;99(7):1994–9.PubMedCrossRef
28.
29.
Martinez M et al. Obstetric outcome after oocyte vitrification and warming for fertility preservation in women with cancer. Reprod Biomed Online. 2014;29(6):722–8.PubMedCrossRef
30.
Porcu E et al. Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer. Reprod Biomed Online. 2008;17(2):265–7.PubMedCrossRef
31.
Sanchez-Serrano M et al. Twins born after transplantation of ovarian cortical tissue and oocyte vitrification. Fertil Steril. 2010;93(1):268.e11–3.CrossRef
32.
Yang D et al. Live birth after the transfer of human embryos developed from cryopreserved oocytes harvested before cancer treatment. Fertil Steril. 2007;87(6):1469.e1–4.CrossRef
33.
Chung K et al. Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. Fertil Steril. 2013;99(6):1534–42.PubMedCrossRef
34.
Meirow D, Schiff E. Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. J Natl Cancer Inst Monogr. 2005;34:21–5.PubMedCrossRef
35.
Agarwal A, Said TM. Implications of systemic malignancies on human fertility. Reprod Biomed Online. 2004;9(6):673–9.PubMedCrossRef
36.
Knopman JM et al. Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil Steril. 2009;91(4 Suppl):1476–8.PubMedCrossRef
37.
Quintero RB et al. Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril. 2010;93(3):865–8.PubMedCrossRef
38.
Klock SC, Zhang JX, Kazer RR. Fertility preservation for female cancer patients: early clinical experience. Fertil Steril. 2010;94(1):149–55.PubMedCrossRef
39.
Domingo J et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril. 2012;97(4):930–4.PubMedCrossRef
40.
Engmann L et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89(1):84–91.PubMedCrossRef
41.
Pal T et al. Fertility in women with BRCA mutations: a case–control study. Fertil Steril. 2010;93(6):1805–8.PubMedCrossRef
42.
43.
Finch A et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril. 2013;99(6):1724–8.PubMedCrossRef
44.
Collins IM et al. Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. J Clin Oncol. 2013;31(31):3920–5.PubMedCrossRef
45.
46.
Michaelson-Cohen R et al. BRCA mutation carriers do not have compromised ovarian reserve. Int J Gynecol Cancer. 2014;24(2):233–7.PubMedCrossRef
47.
van Tilborg TC, Broekmans FJM, Schrijver LH, Mooij TM, Pijpe A, Oosterwijk JC, Verhoef S, Gómez Garcia EB, van Zelst-Stams WAG, Adank MA, van Asperen CJ, van Doorn HC, van Os TAM, Rookus MA, Ausems MGEM. BRCA1/2 mutation carriers do not have earlier natural menopause compared to proven non-carriers: report from the Dutch hereditary breast and ovarian cancer study group (HEBON). Munich, Germany; 2014.
48.
Verpoest W, Elsen E, Mackens S, De Rycke M, Bonduelle M, Van de Velde H, Blockeel C, De Vos M, Polyzos N, Tournaye H. Ovarian response in BRCA1 carriers: a case–control study, in European Soc of Hum Reprod (ESHRE). Munich, Germany; 2014.
49.
Rzepka-Gorska I et al. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat. 2006;100(1):59–63.PubMedCrossRef
50.
Oktay K et al. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol. 2010;28(2):240–4.PubMedCentralPubMedCrossRef
51.
Lin WT et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer. 2013;119(9):1652–9.PubMedCentralPubMedCrossRef
52.
Titus S et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172):172ra21.PubMedCrossRef
53.
Wang ET et al. BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertil Steril. 2014;102(6):1723–8.PubMedCrossRef
54.
Oktay K et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18(1):90–5.PubMedCrossRef
55.
Oktay K et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347–53.PubMedCrossRef
56.
Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online. 2010;20(6):783–8.PubMedCentralPubMedCrossRef
57.
Oktay K et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91(10):3885–90.PubMedCrossRef
58.
59.
Revelli A et al. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol. 2013;29(11):993–6.PubMedCrossRef
60.
Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26(16):2630–5.PubMedCrossRef
61.
Meirow D, et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility—preservation treatment strategies. Fertil Steril. 2014.
62.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.
63.
Davies C et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.PubMedCrossRef
64.
Goldhirsch A et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.PubMedCentralPubMedCrossRef
65.
Senkus E et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi7–23.PubMedCrossRef
66.
Cold S et al. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer. 2005;93(6):627–32.PubMedCentralPubMedCrossRef
67.
Lohrisch C et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006;24(30):4888–94.PubMedCrossRef
68.
Turan V et al. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril. 2013;100(6):1681–5.e1.PubMedCentralPubMedCrossRef
69.
Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil Steril. 2003;80(1):116–22.PubMedCrossRef
70.
Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update. 2012;18(1):73–91.PubMedCrossRef
71.
Bentov Y et al. An ongoing pregnancy from two waves of follicles developing during a long follicular phase of the same cycle. Fertil Steril. 2010;94(1):350.e8–11.CrossRef
72.
Anderson RA, Kinniburgh D, Baird DT. Preliminary experience of the use of a gonadotrophin-releasing hormone antagonist in ovulation induction/in-vitro fertilization prior to cancer treatment. Hum Reprod. 1999;14(10):2665–8.PubMedCrossRef
73.
Bedoschi GM et al. Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet. 2010;27(8):491–4.PubMedCentralPubMedCrossRef
74.
von Wolff M et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2009;92(4):1360–5.CrossRef
75.
Cakmak H et al. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673–80.PubMedCrossRef
76.
Nayak SR, Wakim AN. Random-start gonadotropin-releasing hormone (GnRH) antagonist-treated cycles with GnRH agonist trigger for fertility preservation. Fertil Steril. 2011;96(1):e51–4.PubMedCrossRef
77.
78.
Kuang Y et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014;101(1):105–11.PubMedCrossRef
Metadata
Title
IVF for fertility preservation in breast cancer patients—efficacy and safety issues
Authors
M. Shapira
H. Raanani
D. Meirow
Publication date
01-08-2015
Publisher
Springer US
Published in
Journal of Assisted Reproduction and Genetics / Issue 8/2015
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-015-0519-x

Other articles of this Issue 8/2015

Journal of Assisted Reproduction and Genetics 8/2015 Go to the issue

Editor’s Commentary

The field of fertility preservation comes of age

Fertility Preservation

A new method for evaluating the risk of transferring leukemic cells with transplanted cryopreserved ovarian tissue

Fertility Preservation

In vitro maturation (IVM) of oocytes recovered from ovariectomy specimens in the laboratory: a promising “ex vivo” method of oocyte cryopreservation resulting in the first report of an ongoing pregnancy in Europe

Fertility Preservation

Reference gene selection for real-time quantitative PCR analysis on ovarian cryopreservation by vitrification in mice

Fertility Preservation

Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analogues

Fertility Preservation

Impact of the cryopreservation technique and vascular bed on ovarian tissue transplantation in cynomolgus monkeys